Zoetis/$ZTS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zoetis
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Ticker
$ZTS
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
13,800
ISIN
US98978V1035
Website
Zoetis Metrics
BasicAdvanced
$69B
27.84
$5.57
0.94
$1.86
1.29%
Price and volume
Market cap
$69B
Beta
0.94
52-week high
$194.42
52-week low
$139.70
Average daily volume
3M
Dividend rate
$1.86
Financial strength
Current ratio
1.736
Quick ratio
0.916
Long term debt to equity
116.455
Total debt to equity
145.628
Dividend payout ratio (TTM)
32.25%
Interest coverage (TTM)
15.56%
Profitability
EBITDA (TTM)
3,867
Gross margin (TTM)
70.96%
Net profit margin (TTM)
27.12%
Operating margin (TTM)
37.02%
Effective tax rate (TTM)
20.90%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
15.11%
Return on equity (TTM)
52.09%
Valuation
Price to earnings (TTM)
27.836
Price to revenue (TTM)
7.541
Price to book
14.86
Price to tangible book (TTM)
80.7
Price to free cash flow (TTM)
30.699
Free cash flow yield (TTM)
3.26%
Free cash flow per share (TTM)
505.09%
Dividend yield (TTM)
1.20%
Forward dividend yield
1.29%
Growth
Revenue change (TTM)
6.32%
Earnings per share change (TTM)
7.32%
3-year revenue growth (CAGR)
5.58%
10-year revenue growth (CAGR)
6.84%
3-year earnings per share growth (CAGR)
8.52%
10-year earnings per share growth (CAGR)
16.79%
3-year dividend per share growth (CAGR)
18.66%
10-year dividend per share growth (CAGR)
19.64%
What the Analysts think about Zoetis
Analyst ratings (Buy, Hold, Sell) for Zoetis stock.
Bulls say / Bears say
Zoetis reported a 10% year-over-year revenue increase to $2.19 billion in Q1 FY24, driven by strong performance in the U.S. segment, with sales up 16% year-over-year. (benzinga.com)
Stifel raised its price target for Zoetis to $200 from $180, maintaining a Buy rating, citing the company's strong market positioning and potential for continued growth. (investing.com)
Zoetis received a conditional license from the U.S. Department of Agriculture for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus, indicating progress in expanding its product portfolio. (reuters.com)
BTIG cut its price target for Zoetis to $200 from $225, suggesting potential concerns about the company's valuation or future performance. (tradingview.com)
Zoetis' Q4 2024 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. (seekingalpha.com)
Zoetis' Q4 2024 adjusted EPS of $1.40 beat consensus estimates, but the stock declined due to concerns over slowing growth and cautious 2025 guidance. (benzinga.com)
Data summarised monthly by Lightyear AI. Last updated on 27 May 2025.
Zoetis Financial Performance
Revenues and expenses
Zoetis Earnings Performance
Company profitability
Zoetis News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jul18
Zoetis
Dividend·Ex-dividend
Sept3
Zoetis
Dividend·Payment
$0.50Per share
FAQs
What’s the current market cap for Zoetis stock?
Zoetis (ZTS) has a market cap of $69B as of June 20, 2025.
What is the P/E ratio for Zoetis stock?
The price to earnings (P/E) ratio for Zoetis (ZTS) stock is 27.84 as of June 20, 2025.
Does Zoetis stock pay dividends?
Yes, the Zoetis (ZTS) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $1.864 and the yield is 1.29%. Zoetis has a payout ratio of 32.25% on a trailing twelve-month basis.
When is the next Zoetis dividend payment date?
The next Zoetis (ZTS) dividend payment is scheduled for September 03, 2025.
What is the beta indicator for Zoetis?
Zoetis (ZTS) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.